Rational Use of Ceftriaxone with Calcium Products from the Changes of Rocephin Label

Abstract

Abstract: Objective To provide the information about the clinical safety and rational use of ceftriaxone with calcium products. Methods In order to gain the method of rational use of cetriaxone with calcium products, there is a need to compare the changes of usage and dosage, adverse reactions, attentions and compatibilities about the use of cetriaxone with calcium products in six different editions of rocephin label in our country. Results From the fourth edition in 2009 to the latest one, it has been marked clearly that rocephin and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid but except the neonatal. Conclusion According to the label, using the ceftriaxone with calcium products intravenously in sequential is allowed while it still needs to use carefully in special patients and conditions.

Key words: Key words：ceftriaxone, label, sodium lactate ringer's injection, rational use

CLC Number:

GUAN Shang-wei,,ZHENG Ting-ting,ZHANG Wei. Rational Use of Ceftriaxone with Calcium Products from the Changes of Rocephin Label[J]. Chinese Journal of Pharmacovigilance, 2015, 12(4): 245-248.

References

[1] Mandell L A, Wunderink R G, Anzueto A,et al. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the man-agement of community-acquired pneumonia in adults[J]. Clin Infect Dis，2007，44(Suppl 2):S27-72.
[2] Workowski K A, Berman S. Sexually transmitted diseases treatment guidelines[J]. MMWR Recomm Rep，2010.
[3] WHO. Management of the child with a serious infection or severe malnutrition: Guidelines for care at the first referral level in developing countries[B/OL].[2015-03-05]. http://www.whoint/maternal_child_adolescent/documents/fch_cah_00_1/en/.
[3] WHO. Dept.of Child and Adolescent Health and Development UNICEF. Management of the child with a serious infection or severe malnutrition: guidelines for care at the first-referral level in developing countries[M].Geneva:World Health Organization,2000:55.
[4] 中华医学会,中华医院管理学会药事管理专业委员会,中国药学会医院药学专业委员会,等.抗菌药物临床应用指导原则[J].中华医学杂志,2004,84(22):1857-1862.
[5] Schaed U B,Wedgwoed-Krucko J,Tschaeppeler H.Reversible ceftfia-xone-associated biliary pseudolithiasis in children[J].The Lancet,1988，2(8625):1411- 1413.
[6] Cochat P, Cochat N, Jouvenet M, et al. Ceftriaxone-associated nephrolithiasis[J]. Nephrol Dial Transplant, 1990, 5(11): 974-976.
[7] 许建文,付群.头孢曲松钠与含钙注射液不恰当配伍致药物反应3例[J].儿科药学杂志,2004,10(1):63-63.
[8] Shiffman M L, Keith F B, Moore E W. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility[J]. Gastroenterology, 1990，99（6）:1772-1778.
[9] Lozanovski V J, Gucev Z, Avramoski V J, et al. Ceftriaxone associated urolithiasis in a child with hypercalciuria[J]. Hippokratia, 2011,15（2）:181-183.
[10] Chutipongtanate S,Thongboonkerd V.Ceftriaxone crystallization and its potential role in kidney stone formation[J].Biochemical and Biophysical Research Communications, 2011,406(3):396-402.
[11] Gargollo P C, Barnewolt C E, Pediatric ceftriaxone nephrolithiasis[J]. J Urol, 2005,173(2): 577-578.
[12] Nakai Y, Tokuyama E, Yoshida M, et al. Prediction of incompatibility of ceftriaxone sodium with calcium ions using the ionic product[J]. Yakugaku Zasshi,2010,130(1):95-102.
[13] 国家食品药品监督管理局. 关于修订头孢曲松钠说明书中警示语和注意事项的通知（急件）[EB/OL]. （2007-02-15）[2014-12-18].http://former.sfda.gov.cn/cmsweb/webportal/W473/A64019347.html.
[14] FDA.Information for Healthcare Professionals: Ceftriaxone (marketed as Rocephin) 9/2007 [EB/OL]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProv-iders/DrugSafetyInformationforHeathcareProfessionals/ucm134328.htm,9/2007-18/12/2014.
[15] FDA.Information for Healthcare Professionals: Ceftriaxone(marketed as Rocephin and generics) [EB/OL].（2009-04-21）[2014-12-18].http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationfor-HeathcareProfessionals/ucm084263.htm.
[16] Bradley J S, Wassel R T, Lee L, et al. Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events[J]. Pediatrics,2009 ,123(4)：e609-613.
[17] 马红梅,张洪全,王艺红，等.注射用头孢曲松钠致假性结石的临床观察[J].基层医学论坛,2010,14(31):998-999.
[18] Palanduz A,Yalcin I,Tonquc E.Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children[J].Journal of Clinical Ultrasound,2000，28(4):166-168.
[19] Avci Z,Koktener A,Uras N,et al. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children[J]. Arch Dis Child，2004，89(11):1069-1072.
[20] 梅丹,傅强,王强，等.国产和进口口服钙制剂对体内钙水平影响的比较[J].中国药学杂志,1998, 33 (6):350-354.
[21] Cochat P, Cochat N, Jouvenet M, et al. Ceftriaxone-associated nephrolithiasis[J].Nephrol Dial Transplant ，1990，5(11):974-976.
[22] 王强,张凡,梅丹，等.关于修改头孢曲松说明书一事的探讨[J].中国医院药学杂志, 2008, 28(8): 659-662.
[23] Barry M，Brenner M D. Brenner & Rector's The Kidney[J]. American Journal of Kidney Diseases，2000，36(4):875-876.
[24] 张威,赵海涛,张晓琳，等.头孢曲松钠注射液致儿童假性结石2例[J].中国药物应用与监测,2011,8(2):126-127.
[25] Xiaoming Cong, Xiaojian Gu, Xizhao Sun, et al. Possible Function of Urinary pH and Citrate on the Ceftriaxone-induced Nephr-olithiasis[J]. Urology, 2014，83(1):63-67.